您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

陳彥仰醫師

乳癌、肺癌、大腸直腸癌、胃癌、肝癌、膽胰系統
  • 國語,英語,閩南語
  • 副教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚血液腫瘤科科主任
    • 高雄長庚血液腫瘤科 主治醫師
  • 學歷
    • 長庚大學 臨床醫學研究所 博士
    • 台北醫學大學 醫學系
  • 經歷
    • 高雄長庚醫院內科部 住院醫師
    • 高雄長庚血液腫瘤科 住院總醫師
    • 高雄長庚血液腫瘤科 主治醫師
  • 學會與認證
    • 中華民國癌症醫學會
    • 台灣內科醫學會
  • 論文及期刊發表
    • Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers 2021;13:4584 (SCI;IF=6.639; ONCOLOGY 51/242)

      Yen-Yang Chen,Chao-Long Chen,Chih-Che Lin,Chih-Chi Wang,Yueh-Wei Liu,Wei-Feng Li,Yen-Hao Chen*.
    • A pilot study examining the relationship between environmental contaminants and colorectal cancer at a single medical institute in Taiwan. 台灣衛誌;40:382-393 (non SCI)

      Tian-Huei Chu, Yu-Wei Chou, Sheng-Lun Lin, Su-Fan Liu, Hong-Hwa Chen, Wan-Hsiang Hu, Yen-Yang Chen, Guo-Ping Chang-Chien, Jyun-Huan Chang, Meng-Chi Tsai, Chou-Cheng Huang*.
    • Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure.Frontiers in Oncology. 2021;11:68334 (SCI;IF=6.244; ONCOLOGY 62/242)

      Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang*.
    • The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients. Journal of Gastrointestinal Oncology. 2021;12:297-306. (SCI;IF= 2.892; GASTROENTEROLOGY & HEPATOLOGY 70/92)

      Yu-Yin Liu, Yueh-Wei Liu, Yen-Yang Chen, Shih-Ho Wang, Seng-Kee Chuah, Gong-Kai Huang, Yen-Hao Chen*.
    • Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. PEERJ 2020;8:e10382 (SCI;IF=2.984; MULTIDISCIPLINARY SCIENCES 27/73)

      Yen-Yang Chen, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, Yen-Hao Chen*.
    • Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.PLOS ONE. 2020;15:24079 (SCI;IF=3.240; MULTIDISCIPLINARY SCIENCES 26/73)

      Tai-Jan Chiu, Yi-Ju Chen, Fang-Ying Kuo, Yen-Yang Chen*.
    • Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. Journal of Gastroenterology and Hepatology. 2020;35:1694-1703 (SCI;IF=4.029; GASTROENTEROLOGY & HEPATOLOGY 45/92)

      Chih-Chung Hsu, Keng-Hao Liu, Pei-Hung Chang, Ping-Tsung Chen, Chia-Yen Hung, Shun-Wen Hsueh, Kun-Yun Yeh, Yen-Yang Chen, Chang-Hsien Lu, Yu-Shin Hung, Wen-ChiChou*.
    • External validation of the Besancon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. Pancreatology. 2020;20:116-124 (SCI;IF=3.996; GASTROENTEROLOGY & HEPATOLOGY 46/92)

      Shao-Ming Yu, Chang-Hsien Lu, Keng-Hao Liu, Ping-Tsung Chen, Pei-Hung Chang, Chia-Yen Hung, Shun-Wen Hsueh, Kun-Yun Yeh, Yen-Yang Chen, Yu-Shin Hung, Wen-Chi Chou*.
    • Efficacy and Safety of Uracil Tegafur in Patients with Recurrentor Metastatic Thymic Carcinoma.台灣癌症醫學會雜誌.20207:111-115 (non SCI)

      Shih Yu Huang, Cheng Hua Huang, Harvey Yu Li Su, Yen Hao Chen, Tai?Jan Chiu, Yen?Yang Chen*.
    • Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLOS ONE. 2020;15:23000 (SCI;IF=3.240; MULTIDISCIPLINARY SCIENCES 26/73)

      Yi-Hao Yen, Yu-Fan Cheng, Jing-Houng Wang, Chih-Che Lin, Yen-Yang Chen, Chee-Chien Yong, Yueh-Wei Liu, Jen-Yu Cheng, Chien-Hung Chen, Tsung-Hui Hu*.
    • Effect of S?1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7?year multicenter observational cohort study in Taiwan. Cancer Medicine. 2019;8:2085-2094. (SCI;IF=4.452; ONCOLOGY 107/242)

      Hsiang Lan Lai, Yen Yang Chen, Chang?Hsien Lu, Chia Yen Hung, Yung Chia Kuo, Jen Shi Chen, Hung Chih Hsu, Ping Tsung Chen, Pei Hung Chang, Yu Shin Hung, and Wen Chi Chou*
    • Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. Journal of Clinical Medicine. 2019;8:e1402 4.241. (SCI;IF=4.241,MEDICINE, GENERAL & INTERNAL 39/168)

      Keng-Hao Liu, Chia-Yen Hung, Shu-Wen Hsueh, Pei-Hung Chang, Yen-Yang Chen, Chang-Hsien Lu, Ping-Tsung Chen, Kun-Yun Yeh, Pei-Wei Huang, Ngan-Ming Tsang, Yu-Shin Hung, Wen-Chi Chou*.
    • Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Medicine. 2019;8:5554-5563. 4.452; (SCI;IF=4.452,ONCOLOGY 107/242)

      Pei-Wei Huang, Ching-Fu Chang, Chia-Yen Hung, Shun-Wen Hsueh, Pei-Hung Chang, Kun-Yun Yeh, Jen-Shi Chen, Yen-Yang Chen, Chang-Hsien Lu, Yu-Shin Hung, Wen-Chi Chou*.
    • Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers. 2019;11:57 (SCI;IF=6.639; ONCOLOGY 51/242)

      Ching-Fu Chang,Pei-Wei Huang,Jen-Shi Chen,Yen-Yang Chen,Chang-Hsien Lu,Pei-Hung Chang,Yu-Shin Hung,Wen-Chi Chou*.
    • Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. Journal of Clinical Medicine. 2019;8:1024 4.241. (SCI;IF=4.241;MEDICINE, GENERAL & INTERNAL 39/168)

      Chia-Che Wu, Kun-Ming Rau, Wei-Chieh Lee, Meng-Che Hsieh, Jia-Sin Liu, Yen-Yang Chen, and Harvey Yu-Li Su*.
    • Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Medicine. 2019;8:3471-3478 (SCI;IF=4.452; ONCOLOGY 107/242)

      Shu-Hui Lee,Pei-Hung Chang,Ping-Tsung Chen,Chang-Hsien Lu,Yu-Shin Hung,Ngan-Ming Tsang,Chia-Yen Hung,Jen-Shi Chen,Hung-Chih Hsu,Yen-Yang Chen,Wen-Chi Chou*
    • Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study inTaiwan, 2010–2016. Cancer Management and Research 2019;11:2119-2127 (SCI, IF=3.989; ONCOLOGY 128/242)

      Wen-Chi Chou*, Yen-Yang Chen, Chia-Yen Hung, Jen-Shi Chen, Chang-Hsien Lu, Pei-Hung Chang..
    • MET RON dual inhibitor, BMS 777607, suppresses cholangiocarcinoma cell growth, and MET RON upregulation indicates worse prognosis for intra hepatic cholangiocarcinoma patients. Oncology Reports. 2018;40:1411-1421 (SCI,IF=3.906; ONCOLOGY 133/242)

      Yen YangChen,Chi Tung Cheng, Ren Chin Wu, Chun Yi Tsai, Kun Chun Chiang, Ta Sen Yeh, Ming Huang Chen*, Chun Nan Yeh.
    • Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. Cancers. 2018;10:501 (SCI;IF=6.639; ONCOLOGY 51/242)

      Jen-Shi Chen, Chia-Yen Hung, Hung Chang, Chien-Ting Liu,Yen-Yang Chen, Chang-Hsien Lu, Pei-Hung Chang, Yu-Shin Hung, Wen-Chi Chou*.
    • YIncidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Cancers. 2018;10:432 (SCI;IF=6.639; ONCOLOGY 51/242)

      u-Shin Hung, Jen-Shi Chen, Yen-Yang Chen, Chang-Hsien Lu, Pei-Hung Chang, Wen-Chi Chou*.
    • Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors. Journal of Clinical Medicine. 2018;7:408 (SCI;IF=4.241; MEDICINE, GENERAL & INTERNAL 39/168)

      Chien-Feng Li, Ting-Ting Liu, Jui-Chu Wang, Shih-Chen Yu, Yen-Yang Chen, Fu-Min Fang, Wan-Shan Li, Hsuan-Ying Huang*.
    • Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. Oncology Letters. 2018;16:3070-3082. (non-SCI)

      Jen-Shi Chen*, Chun-Nan Yeh, Chi-Tung Cheng, Chueh-Chuan Yen, Yen-Yang Chen, Shih-Chiang Huang, Kun-Chun Chiang, Ta-Sen Yeh, San-Chi Chen, Ta-Chung Chao, Muh-Hwa Yang, Yee Chao.
    • SIRT1 overexpression is an independent prognosticator for patients with esophageal squamous cell carcinoma.Journal of Cardiothoracic Surgery. 2018;13:25 (SCI;IF=1.637; CARDIAC & CARDIOVASCULAR SYSTEM 123/141)

      Ming-Chun Ma, Tai-Jan Chiu, Hung-I Lu, Wan-Ting Huang, Chien-Ming Lo, Wan-Yu Tien, Ya-Chun Lan, Yen-Yang Chen, Chang-Han Chen, Shau-Hsuan Li*.
    • Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. BMC CANCER.2018;18:227.(SCI;IF= 4.430; ONCOLOGY 109/242)

      Ming-Chun Ma, Yi-Ju Chen, Tai-Jan Chiu, Jui Lan, Chien-Ting Liu, Yi-Ching ChenHsin-Ho Tien & Yen-Yang. Chen*.
    • A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget.2017;8:44121-44130. (non-SCI)

      Chun-Nan Yeh, Ming-Huang Chen, Yen-Yang Chen, Ching-Yao Yang, Chueh-Chuan Yen, Chin-Yuan Tzen, Li-Tzong Chen, Jen-Shi Chen*.
    • Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.Clinical Cancer Research. 2017;23:4908-4918 (SCI;IF=12.531; ONCOLOGY 18/242)

      Chien-Feng Li, Fu-Min Fang, Yen-Yang Chen, Ting-Ting Liu, Ti-Chun Chan, Shih-Chen Yu, Li-Tzong Chen, Hsuan-Ying Huang*.
    • PLCB4 copy gain and PLCs4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget 2017;8:19997-20010. (non-SCI)

      Chien-Feng Li, Ting-Ting Liu, I-Chieh Chuang, Yen-Yang Chen, Fu-Min Fang, Ti-Chun Chan, Wan-Shan Li, and Hsuan-Ying Huang*.
    • Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.International journal of surgery. 2017;39:30-36 (SCI;IF=6.071; SURGERY 15/211)

      Chun-Nan Yeh*, Shang-Yu Wang, Chun-Yi Tsai, Yen-Yang Chen, Ching-Ting Liu, Kun-Chun Chiang, Tsung-Wen Chen, Yu-Yin Liu, Ta-Sen Yeh.
    • Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors. Oncotarget.2016;7:49986-49997. (non-SCI)

      Chien-Feng Li, I-Chieh Chuang, Ting-Ting Liu,Ko-Chin Chen, Yen-Yang Chen, Fu-Min Fang, Shau-Hsuan Li, Tzu-Ju Chen, Shih-Chen Yu, Jui Lan, Hsuan-Ying Huang*.
    • The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia-Pacific Journal of Clinical Oncology.2016;12:396-402 (SCI;IF=2.601; ONCOLOGY 199/242)

      Chien-Ting Liu, Jen-shi Chen, Li-Tzong Chen, Yan-Shen Shan, Chang-Hsien Lu, Yu-Li Su, Fan-Chen Ku, Wen-Chi Chou*, Yen-Yang Chen.
    • A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma. Anticancer research. 2016;36:4249-4258 (SCI;IF=2.480; ONCOLOGY 209/242)

      Chun-Nan Yeh, Shang-Yu Wang, Yen-Yang Chen, Ming-Huang Chen, Kun-Chun Chiang, Chi-Tung Cheng, Chun-Yi Tsai, Chih-Chi Wang, Ta-Sen Yeh*, Tse-Ching Chen.
    • Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. Journal of Cancer. 2016;7:1347-1352 (SCI;IF=4.207; ONCOLOGY 119/242)

      Meng-Che Hsieh,Cheng-Hua Huang,Po-Hui Chiang,Yen-Yang Chen,Yeh Tang,Yu-Li Su*.
    • Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy. International Journal of Urology. 2016;23:385-389 (SCI; IF= 3.369; UROLOGY & NEPHROLOGY 36/90)

      Meng-Che Hsieh, Yu-Li Su,Po-Hui Chiang,Kun-Ming Rau,Yen-Yang Chen,Cheng-Hua Huang*.
    • Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLOS ONE 2015;10:14489 (SCI; IF= 3.240; MULTIDISCIPLINARY SCIENCES 26/73

      Jen-Hao Yeh, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen , Kwong-Ming Kee, Chung-Mou Kuo, Yi-Hao Yen, Yu-Fan Cheng, Yen-Yang Chen, Hsuan-Chi Hsu, Sheng-Nan Lu*.
    • The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.Urologic oncology-seminars and original investigations. 2015 Nov; 33(11) : 495.e9-495.e14 (SCI; IF= 3.498; UROLOGY & NEPHROLOGY 32/90)

      Meng-CheHsieh, Po-Hui Chiang, Kun-Ming Rau, Yen-YangChen, Yu-Li Su, Cheng-Hua Huang*.
    • Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. Oncotargets and therapy. 2015;8:1899-1907 4.147. (SCI; IF= 4.147;BIOTECHNOLOGY & APPLIED MICROBIOLOGY 53/159)

      Chi-Tung Cheng, Yin-Yi Chu, Chun-Nan Yeh*, Shih-Chiang Huang, Ming Huang Chen, Shang-Yu Wang, Chun-Yi Tsai, Kun-Chun Chiang, Yen-Yang Chen, Ming-Chun Ma,Chien-Ting Liu, Tsung-Wen Chen, Ta-Sen Yeh.
    • Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.Medicine 2015;94:1-6. (SCI; IF= 1.889; MEDICINE, GENERAL & INTERNAL 99/168)

      Shih-Chun Chang, Chien-Hung Liao, Shang-Yu Wang, Chun-Yi Tsai, Kun-Chun Chiang, Chi-Tung Cheng, Ta-Sen Yeh, Yen-Yang Chen, Ming-Chun Ma, Chien-Ting Liu, Chun-Nan Yeh*.
    • Multiple Endocrine Neoplasia Type 1 With GastricNeuroendocrine Tumor Presented With Gastric Polyposis. Clinical Gastroenterology and Hepatology. 2015;13:e45 11.382; (SCI; IF=11.382; GASTROENTEROLOGY & HEPATOLOGY 8/92)

      Chien-Ting Liu, Yi-Chun Chiu, and Yen-Yang Chen*.
    • Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study. Translational Oncology. 2014;7:620-625. (SCI; IF=4.243; Oncology 117/242)

      Yen-Yang Chen , Chun-Nan Yeh, Chi-Tung Cheng , Chao-En Wu , Kun-Chun Chiang , Tsung-Wen Chen , Chih-Chi Wang , Jen-Shi Chen , Ta-Sen Yeh
    • Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. Scientific world journal. 2014:16013.(non-SCI)

      Ming-Chun Ma, Yen-Yang Chen, Shau-Hsuan Li, Yu-Fan Cheng, Chih-Chi Wang, Tai-Jan Chiu, Sung-Nan Pei, Chien-Ting Liu, Tai-Lin Huang, Chen-Hua Huang, Yu-Li Su, Yen-Hao Chen, Sheng-Nan Lu, Kun-Ming Rau*.
    • Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget. 2014;5:4071-4086. (non-SCI)

      Chun-Nan Yeh, Chueh-Chuan Yen, Yen-Yang Chen, Chi-Tung Cheng, Shih-Chiang Huang, Ting-Wei Chang, Fang-Yi Yao, Yung-Chan Lin, Yao-Shan Wen, Kun-Chun Chiang, Jen-Shi Chen, Ta-Sen Yeh, Cheng-Hwai Tzeng, Ta-Chung Chao, and Jonathan A. Fletcher.
    • Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) has a Better Survival than GC (Gemcitabine and Cisplatin). 中華民國癌症醫學會雜誌. 2014;1:197-207. (non-SCI)

      Meng-Che Hsieh, Po-Hui Chiang, Kun-Ming Rau, Yen-Yang Chen, Yo-Li Su, Cheng-Hua Huang*.
    • AMACR amplification and overexpression in primary imatinib-naive gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis. Oncotarget. (non-SCI) 2014;5:11588-11603.

      Chien-Feng Li, Li-Tzong Chen, Jui Lan, Fong-Fu Chou, Ching-Yih Lin, Yen-Yang Chen, Tzu-Ju Chen, Shau-Hsuan Li, Shih-Chen Yu, Fu-Ming Fang, Hui-Chun Tai, and Hsuan-Ying Huang*.
    • Imatinib Escalation or Sunitinib Treatment After First-line Imatinib in Metastatic Gastrointestinal Stromal Tumor Patients. Anticancer research. 2014;34:5029-5036. (SCI; IF=2.480; Oncology 209/242)

      Chih-Chieh Hsu, Chiao-En Wu, Jen-Shi Chen, Jeng-Hwei Tseng, Kun-Chun Chiang, Yu-Yin Liu, Chun-Yi Tsai, Chi-Tung Cheng, Tsung-Wen Chen, Yi-Yin Jan, Ta-Sen Yeh, Yen-Yang Chen and Chun-Nan Yeh*.
    • Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1–2 tumor and 1–3 axillary lymph node(s) metastasis. Radiology and Oncology. 2014;48:314-322. (SCI; IF=2.991; Radiology, Nuclear medicine & Medical imaging 65/134)

      Yu-Li Su, Shan-Hsuan Li, Yen-Yang Chen, Hui-Chun Chen, Yen Tang, Cheng-Hua Huang, Fong-Fu Chou, Shih-Chung Wu, and Kun-Ming Rau*.
    • Fas/Fas Ligand Mediates Keratinocyte Death in Sunitinib-Induced Hand-Foot Skin Reaction. Journal of investigative dermatology. 2014; 134: 2768 -2775. (SCI; IF=8.551; Dermatology 4/68)

      Chun-NanYeh, Wen-HungChung, Shih-ChiSu, Yen-YangChen, Chi-TungCheng, Yen-LingLin, Wan-ChunChang, RosalineChung-Yee Hui, Kun-ChunChiang, Tsung-WenChen, Yi-YinJan, Chien-WeiChen, Ting-JuiChen, Chih-HsunYang, Shuen-Iu Hung*.
    • HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease-free survival in patients with gastrointestinal stromal tumours (GISTs). Histopathology. 2013;63:445-454. (SCI; IF=5.087; Pathology 18/77)

      Yu-Ching Wei, Fong-Fu Chou, Chien-Feng Li, Wei-Ming Li, Yen-Yang Chen, Jui Lan, Shau-Hsuan Li, Fu-Min Fang, Tsung-Hui Hu, Shih-Chen Yu, Hock-Liew Eng, Yih-Huei Uen, Yu-Fang Tian, Jui-Chu Wang, Hsuan-Ying Huang*.
    • Brain Metastasis in Patients with Esophageal Squamous Cell Carcinoma: A Single Institute Experience in Southern Taiwan. 中華民國癌症醫學會雜誌. 201329:182-189. (non-SCI)

      Yen-Hao Chen, Yu-Ming Wang, Hung-I Lu, Tao-Chen Lee, Cheng-Hua Huang, Ming-Jang Hsieh, Fu-Min Fang, Kun-Ming Rau, Yen-Yang Chen, Shau-Hsuan Li*.
    • Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Annals of Surgical Oncology 2012;19:3491-3499. (SCI; IF=5.344; Onocology 81/242)

      Chi-Tung Cheng, Shih-Chiang Huang, Ting-Wei Chang, Yi-Yin Jan, Cheng-Hwai Tzeng, Ta-Chung Chao, Yeng-Yang Chen, Ching-Yao Yang, Ching-Liang Ho, Jonathan A Fletcher*.
    • Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Experimental and Therapeutic Medicine. 2012 Aug; 4(2): 231–236 (SCI; IF=2.447; Medcine, Research & Experimental 104/140)

      Kun-Ming Rau, Chao-Cheng Huang, Tai-Jan Chiu, Yen-Yang Chen, Chien-Chang Lu, Chien-Ting Liu, Sung-Nan Pei, and Yu-Ching Wei*.
    • A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer 2012;15:49-55. (SCI; IF=7.370; Gastroenterology & hepatology 18/92)

      Jen-Shi Chen,Yen-Yang Chen,Jen-Sheng Huang,Kun-Yun Yeh,Ping-Tsung Chen,Wen-Chi Shen,Hung-Chih Hsu,Yung-Chung Lin,Hung-Ming Wang* .
    • Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing kit : A decade experience from Taiwan. Translational oncology. 2011 ; 4:328-325. (SCI; IF=3.393; Oncology 97/184)

      Chen YY, Yeh CN*, Tseng JH, Chen JS, Chen TW, Tsai CY, Cheng CT, Jan YY, Chen MF.
    • A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric cancer. 2012;15:49-55. (SCI; IF=1.897; Gastroenterology & hepatology 44/71)

      Jen-Shi Chen, Yen-Yang Chen, Jen-Sheng Huang, Kun-Yun Yeh, Ping-Tsung Chen, Wen-Chi Shen, Hung-Chih Hsu, Yung-Chung Lin and Hung-Ming Wang.
    • Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World journal of gastroenterology.2011;17:2113-2119. (SCI; IF=1.897; Gastroenterology & hepatology 35/71)

      Yen-Yang Chen, Chun-Nan Yeh*, Chi-Tung Cheng, Tsung-Wen Chen, Kun-Ming Rau, Yi-Yin Jan,Miin-Fu Chen.
    • Pemetrexed as third-line chemotherapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) : A retrospective analysis.2011;27:157-164

      Wu chi ache, Tai-jan chiu, Meng-Chih Lin, Jui-Ling Wang, Kun ming Rau, Chen YY , Huang CH*.
    • Chen YH, Lu HI, Huang CH, Rau KM, Chiu YC, Wang YM, Chen YY, Liu CT, Li SH*.The use of trimodality treatment of locally advanced resectable esophageal squamous cell carcinoma: a single institute experience in southern Taiwan. Journal of Cancer Research and Practice. 2011; Oct 27(5): 200-210